Akari Therapeutics Plc (AKTX): Price and Financial Metrics
AKTX Price/Volume Stats
| Current price | $1.19 | 52-week high | $5.50 |
| Prev. close | $1.19 | 52-week low | $1.08 |
| Day low | $1.17 | Volume | 3,900 |
| Day high | $1.20 | Avg. volume | 12,181 |
| 50-day MA | $1.81 | Dividend yield | N/A |
| 200-day MA | $3.02 | Market Cap | 9.43M |
AKTX Stock Price Chart Interactive Chart >
Akari Therapeutics Plc (AKTX) Company Bio
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.
Latest AKTX News From Around the Web
Below are the latest news stories about AKARI THERAPEUTICS PLC that investors may wish to consider to help them evaluate AKTX as an investment opportunity.
Akari Therapeutics to Present at Biotech Showcase 2024NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meet |
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of DirectorsNEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors. “Samir is a long-time investor in Akari and brings to us broad life sciences experience and a track record of multiple successful startup companies. I am pleased to welco |
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferencePositive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and multiple ascending dose (SAD/MAD) testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD) of long-acting PAS-nomacopanBOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoim |
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceBOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference taking place Novemb |
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register NowMIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |
AKTX Price Returns
| 1-mo | -36.02% |
| 3-mo | -55.09% |
| 6-mo | -66.94% |
| 1-year | -66.96% |
| 3-year | -97.46% |
| 5-year | -98.33% |
| YTD | -61.86% |
| 2023 | -66.80% |
| 2022 | -68.67% |
| 2021 | -18.92% |
| 2020 | 5.71% |
| 2019 | 11.46% |
Loading social stream, please wait...